106 related articles for article (PubMed ID: 2678584)
21. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock.
Varpula M; Pulkki K; Karlsson S; Ruokonen E; Pettilä V;
Crit Care Med; 2007 May; 35(5):1277-83. PubMed ID: 17414731
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of plasma levels of fibronectin in septic shock].
Hortells JL; Ibáñez Estella JA; Pérez de Viñaspre S; Sánchez Ibáñez A; González Barrio I
Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):531-5. PubMed ID: 1489793
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Strojan P; Budihna M; Smid L; Vrhovec I; Skrk J
Anticancer Res; 2000; 20(5C):3975-81. PubMed ID: 11268487
[TBL] [Abstract][Full Text] [Related]
26. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
27. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
28. Time course of endothelial damage in septic shock: prediction of outcome.
Hein OV; Misterek K; Tessmann JP; van Dossow V; Krimphove M; Spies C
Crit Care; 2005 Aug; 9(4):R323-30. PubMed ID: 16137344
[TBL] [Abstract][Full Text] [Related]
29. Ferritin levels in children with severe sepsis and septic shock.
Garcia PC; Longhi F; Branco RG; Piva JP; Lacks D; Tasker RC
Acta Paediatr; 2007 Dec; 96(12):1829-31. PubMed ID: 18001337
[TBL] [Abstract][Full Text] [Related]
30. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
31. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
32. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator system in smokers and non-smokers with and without periodontal disease.
Buduneli N; Buduneli E; Kardeşler L; Lappin D; Kinane DF
J Clin Periodontol; 2005 Apr; 32(4):417-24. PubMed ID: 15811061
[TBL] [Abstract][Full Text] [Related]
34. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
35. [Assessment of the release of thyroid hormones in septic shock--prognostic significance].
Borkowski J; Siemiatkowski A; Wołczyński S; Czaban SL; Jedynak M
Pol Merkur Lekarski; 2005 Jan; 18(103):45-8. PubMed ID: 15859546
[TBL] [Abstract][Full Text] [Related]
36. [Peculiar increase of plasma plasminogen activator inhibitor 1 levels in patients with hemophagocytic histiocytosis].
Shimmyozu K; Kadokura N; Itoyama T; Tara M; Maruyama I; Osame M
Rinsho Ketsueki; 1990 Jan; 31(1):127-8. PubMed ID: 2313902
[TBL] [Abstract][Full Text] [Related]
37. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
38. Tight glycemic control may favor fibrinolysis in patients with sepsis.
Savioli M; Cugno M; Polli F; Taccone P; Bellani G; Spanu P; Pesenti A; Iapichino G; Gattinoni L
Crit Care Med; 2009 Feb; 37(2):424-31. PubMed ID: 19114908
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
40. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
